US Patent

US9951016 — Crystalline forms of an NK-1 antagonist

Composition of Matter · Assigned to Helsinn Healthcare SA · Expires 2035-09-25 · 9y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline forms of the NK-1 antagonist 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide.

USPTO Abstract

The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.

Drugs covered by this patent

Akynzeo (NETUPITANT) · Helsinn Hlthcare

Patent Metadata

Patent number: US9951016
Jurisdiction: US
Classification: Composition of Matter
Expires: 2035-09-25
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Helsinn Healthcare SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.